Nicole Ehrhart, MD, presented the results of her preclinical study, Adipose-Derived Mesenchymal Stromal Cells Seeded on Demineralized Bone Matrix Persist and Differentiate When Implanted in a Critical-Sized Rat Femur Defect, which validated AlloSource's AlloStem Cellular Bone Allograft effectiveness in bone formation, according to Yahoo Finance.
Here are five takeaways:
1. In the study, Dr. Ehrhart utilized technology similar to AlloSource's AlloStem Cellular Bone Allograft, with the results showing all study subjects had bone formation within a "critical-sized defect."
2. AlloSource's AlloStem is comprised of partially demineralized allograft bone and adipose-derived mesenchymal stem cells.
3. The AlloStem and autograft bone both contain three properties essential for bone formation, including osteoconduction, osteoinduction and osteogenesis.
4. Dr. Nicole Ehrhart is a surgical oncology professor at Colorado State University Flint Animal Cancer Center in Fort Collins. Journal of Biomaterials and Tissue Engineering will publish her research.
5. One of the nation's largest nonprofit cellular and tissue networks, AlloSource provides more than 200 types of cartilage, cellular, bone, skin and soft-tissue allografts that work to facilitate patient healing.
"Research is an important part of allograft development and the cellular validation from this study tells a story about AlloStem and its ability to help heal patients," said AlloSource's Vice President of Strategy, Development and Growth, Peter Stevens, PhD. "We look forward to our continued work with Dr. Ehrhart and CSU to maximize the gift of tissue donation."
More device news:
Integrated Endoscopy to exhibit nuvis arthroscopic surgery device — 5 highlights
OrthoWorx to create orthopedic medical device powerhouse in Indiana: 6 highlights
EOS signs corporate agreement with Schön Kliniken Hospital Network — 6 takeaways